ABT

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Abbott Laboratories

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Its portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.
CEO
Robert Ford
Employees
109000
Headquarters

100 Abbott Park Rd
Abbott Park, Illinois 60064-3500
Phone: 12246676100
www.abbott.com

News

Animal Based Protein Supplements Global Market Report 2022: Ukraine-Russia War Impact
Nov 24, 2022 11:31am

Major players in the animal-based protein supplements market are Glanbia plc, Abbott Laboratories, CytoSport Inc. , MusclePharm Corporation, Iovate Health Sciences International Inc. , AMCO Proteins, WOODBOLT DISTRIBUTION LLC, Quest Nutrition, NOW Foods, Transparent Labs, The Bountiful Company, Dymatize Enterprises LLC, BPI Sports LLC, JymSupplementScience, RSP Nutrition, and International Dehydrated Foods Inc. Major players in the animal-based protein supplements market are Glanbia plc, Abbott Laboratories, CytoSport Inc. , MusclePharm Corporation, Iovate Health Sciences International Inc. , AMCO Proteins, WOODBOLT DISTRIBUTION LLC, Quest Nutrition, NOW Foods, Transparent Labs, The Bountiful Company, Dymatize Enterprises LLC, BPI Sports LLC, JymSupplementScience, RSP Nutrition, and International Dehydrated Foods Inc.


Source:GlobeNewswire
Abbott Stock: Good Execution, Attractive Valuation (NYSE:ABT)
Nov 24, 2022 08:37am

Abbott is a market leader in medical device businesses and in-vitro diagnostics. Read more to see why ABT offers an attractive long-term business case.


Source:Seeking Alpha
Abbott Labs: Prepare For A Tough 2023 (NYSE:ABT)
Nov 21, 2022 06:01am

Abbott Laboratories faces multiple headwinds that will contract revenue and earnings in the coming year. Click here to read why ABT is a Hold.


Source:Seeking Alpha
Analysts Predict An Abbott Laboratories (NYSE: ABT) Spike?
Nov 17, 2022 18:00pm

Abbott Laboratories (NYSE:ABT) shares, rose in value on Thursday, November 17, with the stock price down by -1.55% to the previous day’s close as strong demand from buyers drove the stock to $102.00. Actively observing the price movement in the recent trading, the stock is buoying the session at $103.61, falling within a range of … Analysts Predict An Abbott Laboratories (NYSE: ABT) Spike? Read More »


Source:Stocks Register
2 Reasons to Buy Abbott Labs and 1 Reason to Sell
Nov 17, 2022 12:26pm

The healthcare company offers growth and value.


Source:The Motley Fool
2 Stocks to Benefit from Medical Device Shortages
Nov 16, 2022 21:54pm

Supply-chain tentacles have held the medical device-making industry in a tight grip. However, this may present upside potential for industry players like Baxter International (NYSE:BAX) and Abbott Labs (NYSE:ABT). The pandemic saw large numbers of patients deferring key medical and surgical procedures due to the lockdowns and the scare of visiting hospitals, which were the hubs of the virus. However, now, medical-device manufacturers are struggling to meet the inflated pent-up demand. The sporadic resurgences of COVID cases in the U.S. have kept the demand for medical devices up as well. The journey from glut to shortage of medical devices has been accelerated by the supply-chain snarls.


Source:TipRanks
Here''s How Much $1000 Invested In Abbott Laboratories 10 Years Ago Would Be Worth Today
Nov 10, 2022 16:52pm

Abbott Laboratories (NYSE: ABT ) has outperformed the market over the past 10 years by 1.79% on an annualized basis producing an average annual return of 12.9%. Currently, Abbott Laboratories has a market capitalization of $178.98 billion. Buying $1000 In ABT: If … Full story available on Benzinga.com


Source:Benzinga
3 Food Processing Dividend Stocks That Could Benefit From Food Shortages Driven By Russia-Ukraine War
Nov 09, 2022 17:51pm

With global supply chain shortages impacting nearly every sector of the economy in the past two years, will global food shortages worsen? As the U.S. experienced a baby food shortage this summer, firms that made it, such as Abbott Laboratories (NYSE: ABT ), could not keep up with the demand due to shortages in supplies and labor constraints . According to Ukraine’s Ministry for Agriculture, roughly 22 million tons of grain are stranded in the country awaiting export. Ukraine supplies up to 16% of the world’s corn exports and more than 40% of the world’s sunflower oil, per the UN Food and Agriculture Organization. Ukraine’s wheat exports from the start of the marketing year (July 2021 to June 2022) through Jan. 17 were 28% higher year-over-year at 16.3 million metric tons, reported SPGlobal. Meanwhile, the African Development Bank reported wheat prices in Africa are up by 45% year-over-year. With Russia making it more difficult for Ukraine to transport … Full story available on Benzinga.


Source:Benzinga
A Senior Delaware Senator Favors These 3 Stocks: CVS, ABT, TSM
Nov 04, 2022 11:53am

Thomas Richard Carper, popularly known as Tom Carper, a Senior U.S. Senator from Delaware, has been trading (buying and selling) some interesting stocks lately. As per Capitol Trades, on October 17, the Democratic party member sold shares of communications services provider Verizon Communications Inc. (NYSE:VZ), media powerhouse The Walt Disney Co. (NYSE:DIS), and chip maker Intel Corp. (NASDAQ:INTC). At the same time, Carper bought shares of healthcare companies CVS Health (NYSE:CVS) and Abbott Laboratories (NYSE:ABT), as well as shares of famed chip maker Taiwan Semiconductor Manufacturing (NYSE:TSM). Let’s take a look at each of these companies and their recent performances.


Source:TipRanks
A2 Milk approved to sell infant formula in America
Nov 03, 2022 09:31am

Sky News Business Editor Ross Greenwood says shares in a2 Milk soared after it announced the US Food and Drug Administration granted temporary approval to sell infant formula in America. “The US has had a shortage of infant formula since one of its major producers, Abbott Nutrition, closed a key plant after a contamination scare,” Mr Greenwood said. “A2''s local rival Bubs was initially granted approval to sell into the US to ease supply issues, the company capitalised on it with a high-profile campaign as it flew its product to America. “A2 originally did not gain approval - it''s now been given access for its a2 Platinum zero to six months and six to 12 months ranges, which it says will be sold at major US outlets.”


Source:Herald Sun Australia
Analysts Advise You To Maintain Your Position In Abbott Laboratories (NYSE: ABT)
Nov 01, 2022 19:00pm

Abbott Laboratories (NYSE:ABT) traded at $99.56 at last check on Tuesday, November 01, made an upward move of 0.63% on its previous day’s price. Looking at the stock we see that its previous close was $98.94 and the beta (5Y monthly) reads 0.74 with the day’s price range being $98.15 – $99.50. The company has … Analysts Advise You To Maintain Your Position In Abbott Laboratories (NYSE: ABT) Read More »


Source:Stocks Register
Eli Lilly cuts annual profit forecast on stronger dollar
Nov 01, 2022 12:22pm

Eli Lilly and Co on Tuesday cut its annual profit forecast for the third time, as a stronger dollar piled more pressure on the drugmaker struggling with lower insulin prices and generic competition for its cancer drug. The company’s shares fell nearly 4% in premarket trading as the forecast cut overshadowed strong performance by its newly approved diabetes drug. Eli Lilly now expects adjusted full-year earnings of $7.70 to $7.85 per share, compared to its prior forecast of $7.90 to $8.05. The drugmaker also trimmed its full-year revenue forecast to a range of $28.5 billion and $29 billion, from its previous expectation of $28.8 billion and $29.3 billion, citing an additional $300 million hit from the dollar since August. Multinational companies such as Abbott Laboratories and Johnson & Johnson have been hit by the dollar’s strength against a basket of currencies. Lilly flagged a total impact of about $1 billion from the strong dollar for the full year. The company posted better-than-expected results for the third quarter, as demand for its recently approved diabetes drug, Mounjaro, helped counter declining sales of its diabetes and cancer treatments.


Source:Business Recorder
Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Abbott Laboratories (ABT) Investors of Class Action and to Actively Participate | MarketScreener
Oct 31, 2022 15:02pm

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Abbott Laboratories and certain of its officers, on behalf of all… | October 31, 2022


Source:MarketScreener
Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Abbott Laboratories (ABT) Investors of Class Action and to Actively Participate
Oct 31, 2022 15:00pm

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Abbott Laboratories (“Abbott” or “the Company”) (NYSE: ABT) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Abbott securities between February 19, 2021 to June 8, 2022, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s s


Source:Business Wire
5 Best Healthcare Dividend Stocks To Buy Now
Oct 31, 2022 13:07pm

In this article, we discuss 5 best healthcare dividend stocks to buy now. If you want to see more stocks in this selection, check out 11 Best Healthcare Dividend Stocks To Buy Now. 5. Abbott Laboratories (NYSE:ABT) Number of Hedge Fund Holders: 61 Dividend Yield as of October 28: 1.89% Abbott Laboratories (NYSE:ABT) is an […]


Source:Insider Monkey
ABT IMPORTANT DEADLINE TOMORROW: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Abbott Laboratories Investors to Secure Counsel Before Important October 31 Deadline in Securities Class Action – ABT
Oct 30, 2022 22:30pm

NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abbott Laboratories (NYSE: ABT) between February 19, 2021 and June 8, 2022, both dates inclusive (the “Class Period”), of the important October 31, 2022 lead plaintiff deadline .


Source:GlobeNewswire
ABBOTT LABORATORIES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Abbott Laboratories - ABT
Oct 29, 2022 02:50am

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 31, 2022 to file lead plaintiff applications in a securities class action lawsuit against Abbott Laboratories (NYSE: ABT), if they purchased the Company’s shares between February 19, 2021 to June 8, 2022, inclusive (the “Class Period”). This action is pending in the United States District Court for the Nor


Source:Business Wire
Are You Optimistic About Abbott Laboratories (ABT)’s Long-Term Opportunities?
Oct 27, 2022 17:05pm

Diamond Hill Capital, an investment management company, released its “Large Cap Strategy” third-quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the strategy returned -5.23% net of fees compared to a -4.61% return for the Russell 1000 Index. Holdings in the technology and consumer discretionary sectors led to […]


Source:Insider Monkey
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Latch, Azure, Abbott, and TuSimple and Encourages Investors to Contact the Firm
Oct 27, 2022 01:00am

NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Latch, Inc. (NASDAQ: LTCH), Azure Power Global Limited (NYSE: AZRE), Abbott Laboratories (NYSE: ABT), and TuSimple Holdings, Inc. (NASDAQ: TSP). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.


Source:GlobeNewswire
Abbott draws Neutral rating at Mizuho on COVID headwinds, infant formula issue (NYSE:ABT)
Oct 26, 2022 18:38pm

Mizuho Securities launched its coverage on Abbott Laboratories (ABT) with a Neutral rating on Wednesday, arguing that the pressure on COVID testing and issues surrounding its infant…


Source:Seeking Alpha
Immunohematology Market in Europe is projected to expand at a significant CAGR to 2025 | TMR Study
Oct 25, 2022 19:30pm


Source:Kwhen Finance
ABT APPROACHING DEADLINE: ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Abbott Laboratories Investors With Losses Over $100K to Secure Counsel Before Important October 31 Deadline in Securities Class Action - ABT
Oct 23, 2022 10:22am

NEW YORK, Oct. 23, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abbott Laboratories (NYSE: ABT) between February 19, 2021 and June 8, 2022, both dates inclusive (the "Class Period"), of the important October 31, 2022…


Source:PR Newswire
Is Abbott Laboratories Still a Good Dividend Stock to Buy?
Oct 22, 2022 09:21am

Third-quarter results were less than encouraging on the surface, but what do they say about the road ahead for Abbott Laboratories?


Source:The Motley Fool
Cryptococcosis Treatment Market 2022: Industry Analysis, Opportunities, Demand, Top Players and Growth Forecast 2029 |Abbott Laboratories, Valeant Pharmaceuticals, Pfizer
Oct 21, 2022 18:23pm

Cryptococcosis, also known as crypto coccus, cryptococcal meningitis is a disease that can be deadly if it is not treated early on. Cryptococcosis is caused by the growth of yeast cells (pink/red dots) under the skin. These pink red spots


Source:OpenPR
Insights on the DNA Diagnostics Global Market to 2032 - by Product Type, Technology, Application, End-user and Region - ResearchAndMarkets.com
Oct 21, 2022 12:30pm


Source:Kwhen Finance
ABT FINAL DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Abbott Laboratories Investors with Losses in Excess of $100K to Secure Counsel Before Important October 31 Deadline in Securities Class Action – ABT
Oct 20, 2022 20:11pm

NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abbott Laboratories (NYSE: ABT) between February 19, 2021 and June 8, 2022, both dates inclusive (the “Class Period”), of the important October 31, 2022 lead plaintiff deadline .


Source:GlobeNewswire
Daily Market Comment – Wall Street breaks winning streak as Treasury yields rise
Oct 20, 2022 08:36am

Rising Treasury yields weigh on stocks US dollar outperforms all the other majors Canadian inflation data beats forecast Wall Street in the red as yields hit fresh multi-year highs Wall Street closed in the red on Wednesday, breaking its two-day winning streak due to rising Treasury yields and weakness in the Abbott Laboratories stock, as the firm reported lower-than-expected growth in international medical device sales due to a strong dollar and supply challenges in China. The yield on the 10-year [..]


Source:XM
Piramal Pharma Gets Locked in Lower Circuit
Oct 20, 2022 01:18am

The Ajay Piramal entity’s listing follows the demerger from parent Piramal Enterprises (PEL) as part of an exercise to simplify its structure. Shareholders of PEL were entitled to four shares of Piramal Pharma for every share they held. The group made a re-entry into pharma 10 years after selling its healthcare business to NYSE-listed pharma giant Abbott Labs for $2.5 billion then.


Source:Economic Times India
3 Stocks Set to Soar From 52-Week Lows
Oct 19, 2022 20:39pm

The stock market remains near 52-week lows, and it might be the time to start looking for stocks to buy at a discount. Following September’s inflation figures, things don’t appear to change soon. The consumer price index rose 8.2% through September. The result was higher than expected and suggested that the Fed has further to go in reducing the number. That makes it all but certain that the Fed will increase interest rates another 75 basis points on Nov. 1, when it next convenes. Major indexes remain down significantly. Each of the Dow Jones , Nasdaq , and the S&P 500 are near 52-week lows. And as we near Nov. 1 and the Fed’s next rate decision, they are likely to fall to new lows. None of that is particularly good news overall. Individual stocks should continue to slide. Recession fears will grow. People will suffer. The silver lining, if there is one, is that investors can still find deals. A few stocks to buy appear ready to move upward as tailwinds put them in a stronger position than most others.


Source:InvestorPlace
Equities close lower as rise in yields overshadows earnings
Oct 19, 2022 20:01pm

NEW YORK — U.S. stocks snapped a two-day streak of gains on Wednesday as weakness in shares of Abbott Laboratories and a rise in Treasury yields sapped momentum from the current earnings season and outweighed a surge in Netflix Inc shares. The yield on the 10-year U.S. Treasury note touched its highest level in more […]


Source:Financial Post
Rise in yields weighs on stocks, overshadows earnings
Oct 19, 2022 18:51pm

NEW YORK — U.S. stocks retreated on Wednesday after two straight days of gains, as weakness in shares of Abbott Laboratories and a climb in Treasury yields took some momentum away from the current earnings season and outweighed a surge in Netflix Inc shares. The yield on the 10-year U.S. Treasury note touched its highest […]


Source:Financial Post
Why Abbott Laboratories Stock Is Slumping Today
Oct 19, 2022 18:10pm

A potential drop-off in COVID-19 testing sales is weighing on the healthcare giant''s shares today.


Source:The Motley Fool
Abbott Labs PT Lowered to $110 at Evercore ISI
Oct 19, 2022 17:31pm

https://www.investing.com/news/pro/abbott-labs-pt-lowered-to-110-at-evercore-isi-432SI-2916355


Source:Investing.com
Rapid Covid Tests Can’t Keep Abbott Healthy Forever
Oct 19, 2022 17:25pm

While Abbott Laboratories beat analysts’ expectations due to demand for Covid-19 at-home tests, a decline by its medical-device business and broader headwinds helped send its shares down.


Source:The Wall Street Journal
Rapid Covid Tests Can''t Keep Abbott Healthy Forever
Oct 19, 2022 17:25pm

While Abbott Laboratories beat analysts’ expectations due to demand for Covid-19 at-home tests, a decline by its medical-device business and broader headwinds helped send its shares down.


Source:The Wall Street Journal
Abbott Labs Earnings, Revenue Beat in Q3
Oct 19, 2022 11:34am

https://www.investing.com/news/stock-market-news/abbott-labs-earnings-revenue-beat-in-q3-2915971


Source:Investing.com
Abbott Laboratories raises full-year profit guidance, Non-GAAP EPS of $1.15 beats by $0.21, revenue of $10.4B beats by $750M
Oct 19, 2022 11:33am

Abbott Laboratories (ABT): Q3 Non-GAAP EPS of $1.15 beats by $0.21.Revenue of $10.4B (-4.8% Y/Y) beats by $750M.Abbott is raising its full-year 2022 EPS guidance


Source:Seeking Alpha
Vitamin Capsule Market Will Generate New Growth Opportunities by 2022-2030 | Major Players Bayer AG, Nature''s Bounty, Abbott Laboratories
Oct 18, 2022 12:29pm

The new research study that is being offered here is an excellent compilation of numerous analyses of important elements of the Global Vitamin Capsule Market. It clarifies how the Vitamin Capsule market is anticipated to expand globally over the course


Source:OpenPR
MOORE KUEHN ENCOURAGES INVESTORS OF ABBOTT LABORATORIES TO CONTACT LAW FIRM
Oct 18, 2022 03:58am

NEW YORK, Oct. 17, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against: Abbott Laboratories ("Abbott" or the "Company") (NYSE: ABT) ***Please contact fmoore@moorekuehn.com Abbott is a medical…


Source:PR Newswire
Tesla Shares Have A Supporter in Congress: House Rep. McKinley Also Likes These 2 Dividend Stocks
Oct 17, 2022 19:23pm

Republican Congressman David McKinley recently purchased $1,000 to $15,000 shares in Tesla (NASDAQ: TSLA ) for a price of $300.80 per share, in an undisclosed position , per Capitol Trades. After McKinley’s purchase, the Austin, Texas-based car maker continued to sink lower, as his position is now down roughly 26.5% in less than a month. McKinley, who represents West Virginia and sits on the committee for energy and commerce, sold shares in several companies, including Abbott Laboratories (NYSE: ABT ), CarMax Inc. (NYSE: KMX ), S&P Global Inc. (NYSE: SPGI ) and Stanley Black & Decker Inc. (NYSE: SWK ) , … Full story available on Benzinga.com


Source:Benzinga
Abbott Labs: Shares Remain Expensive While In A Technical Downtrend Ahead Of Earnings
Oct 17, 2022 15:26pm

Abbott Laboratories might have more downside room to go based on bearish technical momentum. Click here to read why ABT should be bought on a bigger dip.


Source:Seeking Alpha
Morgan Stanely says large cap healthcare remains attractive amid macro concerns (NYSE:ABT)
Oct 17, 2022 14:34pm

Despite a backdrop of macro uncertainty, Morgan Stanley analysts led by Michael Wilson reiterated their constructive view on Healthcare, arguing on Monday that the large-cap stocks in…


Source:Seeking Alpha
Abbott Says Recent Recall Of Some Bottles Of Infant Formula Will Not Hamper Supply
Oct 17, 2022 11:37am

Abbott Laboratories (NYSE: ABT ) is voluntarily recalling some ready-to-feed baby formula liquid products, including Similac-branded items, due to inadequate sealing of some bottle caps. The products included in the recall were manufactured at the Columbus, Ohio, manufacturing facility. The recalled lots have bottle caps that may not have been sealed completely, resulting in spoilage. If a spoiled product is consumed, gastrointestinal symptoms such … Full story available on Benzinga.com


Source:Benzinga
Abbott Q3 Earnings Preview: I''m Still Not A Buyer (NYSE:ABT)
Oct 16, 2022 15:00pm

Abbott will report its Q3 earnings results on October 19. Click here to see my thoughts on its upcoming earnings and why I''m not buying ABT stock now.


Source:Seeking Alpha
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Abbott Laboratories Investors With Losses to Secure Counsel Before Important October 31 Deadline in Securities Class Action - ABT
Oct 15, 2022 10:18am

NEW YORK, Oct. 15, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abbott Laboratories (NYSE: ABT) between February 19, 2021 and June 8, 2022, both dates inclusive (the "Class Period"), of the important October 31, 2022…


Source:PR Newswire
Abbott Nutrition recalls certain baby formula products over risk of spoilage
Oct 14, 2022 23:05pm

Abbott Nutrition issued a voluntary recall for some of its baby formula products on Friday over a risk of spoilage. Abbott said in a post on its website that it is recalling certain lots of its 2-fluid-ounce bottles of Ready-to-Feed liquid products for infants and children because a small percentage of the bottles have bottle…


Source:The Hill
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Abbott, TuSimple, Kohl''s, and Bed Bath & Beyond and Encourages Investors to Contact the Firm
Oct 13, 2022 00:39am

NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Abbott Laboratories (NYSE: ABT ), TuSimple Holdings, Inc. (NASDAQ: TSP ), Kohl''s Corporation (NYSE: KSS ), and Bed Bath & Beyond, Inc. (NASDAQ: BBBY ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Abbott Laboratories (NYSE: ABT ) Class Period: February 19, 2021 – June 8, 2022 Lead Plaintiff Deadline: October 31, 2022 Abbott manufactures various forms of infant formula including formula sold under the brand names Similac, Alimentum, and EleCare. Prior to February 2022, Abbott had produced 40% of the United States'' infant formula. Of that amount, nearly half was produced in its manufacturing facility in Sturgis, MI. On February 17, 2022, the US Food and Drug Administration ("FDA") announced it was investigating four consumer complaints of infant illness related to powdered infant formula produced by Abbott in Sturgis.


Source:Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Abbott, TuSimple, Kohl’s, and Bed Bath & Beyond and Encourages Investors to Contact the Firm
Oct 13, 2022 00:39am

NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Abbott Laboratories (NYSE: ABT), TuSimple Holdings, Inc. (NASDAQ: TSP), Kohl’s Corporation (NYSE: KSS), and Bed Bath & Beyond, Inc. (NASDAQ: BBBY). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.


Source:GlobeNewswire
Warren accuses Abbott Nutrition of years-long cover-up campaign on infant formula risks
Oct 12, 2022 17:00pm

Sen. Elizabeth Warren (D-Mass.) sent a letter Wednesday to Abbott Nutrition accusing the company of employing "abusive legal tactics" to cover up health risks with its powdered infant formula product — safety concerns she said the business has been aware of for decades. In the letter, an early version of which was provided exclusively to…


Source:The Hill
Levi & Korsinsky Notifies Abbott Laboratories Investors of a Class Action Lawsuit and Upcoming Deadline
Oct 12, 2022 15:43pm

Levi & Korsinsky, LLP notifies investors in Abbott Laboratories of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Abbott investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all […]


Source:iCrowdNewswire
Abbott Laboratories (NYSE: ABT) Has Been Trading Down. What Are The Prospects For The Future?
Oct 12, 2022 15:00pm

Abbott Laboratories (NYSE:ABT) traded at $101.75 at close of the session on Tuesday, 10/11/22, made an upward move of 0.61% on its previous day’s price. Looking at the stock we see that its previous close was $101.13 and the beta (5Y monthly) reads 0.74 with the day’s price range being $100.09 – $102.75. The company … Abbott Laboratories (NYSE: ABT) Has Been Trading Down. What Are The Prospects For The Future? Read More »


Source:Stocks Register
4 Dividend Stocks Yielding 4%+
Oct 11, 2022 20:15pm

The market continues its downward trend. The U.S. Federal Reserve is raising interest rates in response to high inflation . Consequently, investors are selling because they fear high interest rates will cause a recession. Adding to investors’ negative sentiment are record drought in many places in the world and Russia’s invasion of Ukraine. On the other hand, the current bear market has created some deals. Stocks overvalued for years are now undervalued or at least fairly valued. Moreover, dividend yields have risen to the highest in a decade for some stocks. Below we discuss four dividend stocks yielding 4%+ that are also undervalued. O Realty Income $58.19 NEP NextEra Energy Partners $72.19 ABBV AbbVie $142.59 KMB Kimberly-Clark $111.88 Realty Income (O) Source: Shutterstock Realty Income (NYSE: O ) is a real estate investment trust ( REIT ) that operates under a single-tenant, triple-net lease structure. The company develops and purchases commercial real estate and rents it to retail chains.


Source:InvestorPlace
Ex-Dividend Dates are Fast Approaching for These 3 Stocks
Oct 11, 2022 12:56pm

Investors looking for dividend stocks might want to grab these three well-known names before they hit their ex-dividend dates. As a bonus, each of these stocks is at or near its 52-week low, so you can buy it at a bargain price while benefitting from its dividend. Accenture - ACN Accenture, the professional services company, has an ex-dividend date of Wednesday, October 12. Currently trading at $257.85, its 52-week low was $254.27. ACN''s dividend amount per share is $1.12. Abbott Labs - ABT Abbott Labs, which creates pharmaceutical and healthcare products, will reach its ex-dividend date on Thursday, October 13. The stock is currently trading at $101.


Source:TipRanks
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Abbott Laboratories Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABT
Oct 08, 2022 02:10am

NEW YORK, Oct. 7, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abbott Laboratories (NYSE: ABT) between February 19, 2021 and June 8, 2022, both dates inclusive (the "Class Period"), of the important October 31, 2022…


Source:PR Newswire
ABT DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Abbott Laboratories (ABT) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Pending
Oct 05, 2022 20:58pm

SAN FRANCISCO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Abbott Laboratories (NYSE: ABT) investors who suffered significant losses to submit your losses now .


Source:GlobeNewswire
ABT SHAREHOLDER ALERT: ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Abbott Laboratories Investors to Secure Counsel Before Important Deadline in Securities Class Action – ABT
Oct 03, 2022 20:15pm

NEW YORK, Oct. 03, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abbott Laboratories (NYSE: ABT) between February 19, 2021 and June 8, 2022, both dates inclusive (the “Class Period”), of the important October 31, 2022 lead plaintiff deadline .


Source:GlobeNewswire
Minimally Invasive Medical Devices Reshape Patient Care Capabilities
Sep 29, 2022 13:00pm

FinancialBuzz.com News Commentary NEW YORK , Sept. 29, 2022 /PRNewswire/ -- Among the numerous technologies that help transform the medical device market are the Internet of Things (IoT), machine learning and advanced 3D printing. For instance, IoT is increasingly being used in healthcare to promote active patient engagement and patient-centric service delivery through advanced devices that are constantly connected with each other. Overall, the patient monitoring device market is a large and diverse segment of the medical device industry. In recent years, due to the pandemic and the pressure that hospitals and medical professionals have experienced because of the virus, this segment has gained even more popularity. In fact, the Food and Drug Administration (FDA) has recognized the role remote monitoring devices could play in the industry following the pandemic and even changed its guidance on the use of non-invasive remote monitoring devices for patient care during the public health emergency.


Source:Benzinga
ROSEN, A LONGSTANDING LAW FIRM, Encourages Abbott Laboratories Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABT
Sep 28, 2022 19:15pm

NEW YORK, Sept. 28, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abbott Laboratories (NYSE: ABT) between February 19, 2021 and June 8, 2022, both dates inclusive (the "Class Period"), of the important October 31, 2022…


Source:PR Newswire
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Abbott Laboratories (ABT) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Pending
Sep 27, 2022 18:01pm

SAN FRANCISCO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Abbott Laboratories (NYSE: ABT) investors who suffered significant losses to submit your losses now .


Source:GlobeNewswire
7 Vaccine Stocks to Sell ASAP Now That the ‘Pandemic’s Over’
Sep 27, 2022 10:00am

As people acclimatize to the new normal, it’s time to look at some vaccine stocks to sell. Instead of relying primarily on vaccines and antiviral drugs, the government let people manage infections. Once infected with the less fatal strain, Omicron, people would isolate themselves for a few days and then return to work. By shifting away from its reliance on drug companies, investors must recognize there are vaccine stocks that it’s time to sell. The government cut orders for vaccines and antiviral drugs, which already is hurting vaccine stocks. People realized that the vaccine specific to the Delta variant offered minimal protection against the current strains. As Omicron sub-variants emerge, health organizations will evaluate the effectiveness of bivalent vaccines first. Investors should brace for a sharp drop in vaccine and test kit sales. Those are the vaccine stocks to sell. In addition, companies that depend on antiviral sales risk underperforming. Still, their revenue drop is less severe.


Source:InvestorPlace
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Humanigen, Latch, Azure, and Abbott and Encourages Investors to Contact the Firm
Sep 27, 2022 01:00am

NEW YORK, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Humanigen, Inc. (NASDAQ: HGEN), Latch, Inc. (NASDAQ: LTCH), Azure Power Global Limited (NYSE: AZRE), and Abbott Laboratories (NYSE: ABT). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.


Source:GlobeNewswire
Oncology Nutrition Market to Surpass US$ 4.79 Bn by 2032: Rising Demand to Promote Cancer Patients'' Quality of Life to Boost Growth | Future Market Insights, Inc.
Sep 26, 2022 14:00pm

The oncology nutrition market in the United States is expected to be worth US$ 412.6 million. The U.S. presently holds 35.62% of the global oncology nutrition market share. Demand for oncology nutrition is predicted to increase in the United States, fueled by rising spending on various cancer medicines. NEWARK, DE / ACCESSWIRE / September 26, 2022 / The adoption of oncology nutrition is likely to grow at an average CAGR of 8.9% during the forecast period. The oncology nutrition market size is estimated to be valued at US$ 2.04 Bn in 2022 and is projected to be valued at US$ 4.79 Bn by 2032. The significant increase in nutritional waste and risk among cancer patients is expected to boost the demand for oncology nutrition. Participants in the market environment are currently examining the potential benefits of a multidisciplinary strategy, where concentrated nutrition is believed to be critical to enhancing cancer treatment standards. Over the estimated period, the oncology nutrition market is expected to benefit from increasing research and development efforts as well as the launch of cutting-edge products for cancer patients.


Source:Accesswire